Profile of Shionogi-GlaxoSmithKline
Joint Venture
In October 2001, Shionogi & Co, Ltd. and GlaxoSmithKline entered into
a joint venture to develop and market several drugs in the US and in major
European markets.
Compounds currently under development in the
joint venture
349572, for HIV infection
265744, for HIV infection
247303, for HIV infection
Press releases related to the Shionogi-GlaxoSmithKline
Joint Venture
August 14, 2006 -- GlaxoSmithKline and Shionogi
Complete Initial Clinical Study for HIV Integrase Inhibitor
July 10,
2002 -- Results of first human trial of a new class of anti-HIV drugs
reported by Shionogi-GSK
October
23, 2001 -- Final agreement reached on GSK-Shionogi joint venture
July 24, 2001 -- GSK and Shionogi
to enter global multi-product development and commercialization alliance
|
|
